Genome sequence of enterovirus D68 from St. Louis, Missouri, USA by Wylie, Kristine M et al.




Genome sequence of enterovirus D68 from St.
Louis, Missouri, USA
Kristine M. Wylie
Washington University School of Medicine in St. Louis
Todd N. Wylie
Washington University School of Medicine in St. Louis
Anthony Orvedahl
Washington University School of Medicine in St. Louis
Richard S. Buller
Washington University School of Medicine in St. Louis
Brandi N. Herter
Washington University School of Medicine in St. Louis
See next page for additional authors
Follow this and additional works at: http://digitalcommons.wustl.edu/open_access_pubs
This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been accepted for inclusion in Open
Access Publications by an authorized administrator of Digital Commons@Becker. For more information, please contact engeszer@wustl.edu.
Recommended Citation
Wylie, Kristine M.; Wylie, Todd N.; Orvedahl, Anthony; Buller, Richard S.; Herter, Brandi N.; Magrini, Vincent; Wilson, Richard K.;




Kristine M. Wylie, Todd N. Wylie, Anthony Orvedahl, Richard S. Buller, Brandi N. Herter, Vincent Magrini,
Richard K. Wilson, and Gregory A. Storch
This open access publication is available at Digital Commons@Becker: http://digitalcommons.wustl.edu/open_access_pubs/3598
  5. Sukehiro N, Kida N, Umezawa M, Murakami T, Arai N,  
Jinnai T, et al. First report on invasion of yellow fever mosquito, 
Aedes aegypti, at Narita International Airport, Japan in August 
2012. Jpn J Infect Dis. 2013;66:189–94. http://dx.doi.org/10.7883/
yoken.66.189
  6. National Institute of Infectious Diseases, Infectious Disease  
Surveillance Center [cited 2014 Sep 14]. http://idsc.nih.go.jp/ 
disease/dengue/idwr1122/sokuhou01.gif
  7. Taniguchi K, Yoshida M, Sunagawa T, Tada Y, Okabe N. Imported 
infectious diseases and surveillance in Japan. Travel Med Infect 
Dis. 2008;6:349–54. http://dx.doi.org/10.1016/j.tmaid.2008.07.001
Address for correspondence: Gotaro Kojima, Japan Green Medical 
Centre, 10 Throgmorton Ave, London EC2N 2DL, UK; email: 
gotarokojima@yahoo.co.jp
Genome Sequence  
of Enterovirus D68 from  
St. Louis, Missouri, USA
Kristine M. Wylie, Todd N. Wylie, 
Anthony Orvedahl, Richard S. Buller,  
Brandi N. Herter, Vincent Magrini,  
Richard K. Wilson, and Gregory A. Storch
Author affiliation: Washington University School of Medicine,  
St. Louis, Missouri, USA
DOI: http://dx.doi.org/10.3201/eid2101.141605
To the Editor: During the current (2014) enterovirus/
rhinovirus season in the United States, enterovirus D68 
(EV-D68) is circulating at an unprecedented level. As of 
October 6, 2014, the Centers for Disease Control and Pre-
vention (CDC) had confirmed 594 cases of EV-D68 in-
fection in 43 states and the District of Columbia (http://
www.cdc.gov/non-polio-enterovirus/outbreaks/EV-D68-
outbreaks.html); the actual number of cases was undoubt-
edly much higher. In mid-August, hospitals in Missouri and 
Illinois noticed an increased number of patients with severe 
respiratory illness (1). We observed this pattern at St. Louis 
Children’s Hospital in St. Louis, Missouri.
Resources for studying this virus are limited. Before 
the current season, only 7 whole-genome sequences and 
5 additional complete coding sequences of the virus were 
available. Therefore, determining whether there are ge-
nomic elements associated with rapid spread or severe and 
unusual disease was not possible. 
To address these limitations, we determined the com-
plete coding sequence of 1 strain from St. Louis by using 
high-throughput sequencing of nucleic acid from a clini-
cal sample. To evaluate the sequence diversity in EV-D68 
strains circulating in the St. Louis metropolitan area, we 
also generated partial-genome sequences from 8 more EV-
D68–positive clinical samples from St. Louis. During the 
preparation of this article, CDC generated and submitted to 
GenBank 7 complete or nearly complete genome sequences 
from viruses obtained from the Midwest. We documented 
the diversity of the sequences of strains from St. Louis and 
compared them to publicly available sequences.
The methods are described in brief here and in more 
detail in the online Technical Appendix (http://wwwnc.
cdc.gov/EID/article/21/1/14-1605-Techapp1.pdf). This 
study was conducted under a protocol approved by the Hu-
man Research Protection Office of Washington University 
in St. Louis. 
Patients were categorized retrospectively as having 
mild, moderate, or severe disease if they had been dis-
charged home from the emergency unit, admitted to general 
wards, or admitted to the pediatric intensive care unit, re-
spectively. Residual material from a subset of nasopharyn-
geal specimens positive for rhinovirus/enterovirus (tested 
by the BioFire FilmArray Respiratory Panel [BioFire Diag-
nostics, Salt Lake City, UT, USA] at the Clinical Virology 
Laboratory, St. Louis Children’s Hospital) was selected for 
high-throughput sequencing. Total nucleic acid was extract-
ed from clinical samples by using NucliSENS easyMAG 
(bioMérieux, Marcy l’Etoile, France) and used to make 
dual-indexed sequencing libraries. Enterovirus/rhinovirus 
sequences were enriched by using a NimbleGen custom 
sequence capture reagent (Roche/NimbleGen, Madison, 
WI, USA), which as of February 2014 was selective for all 
complete enterovirus and rhinovirus genomes in GenBank. 
Sequence data were generated on an Illumina HiSeq 2500 
(Illumina Inc., San Diego, CA, USA). Sequences were as-
sembled with IDBA-UD (2) and manually improved. The 
most contiguous genome was annotated by using VIGOR 
(3). Publicly available sequences were downloaded and 
compared by using the National Institute of Allergy and 
Infectious Diseases Virus Pathogen Resource (http://www.
viprbrc.org) (4). Variants were identified by using VarScan 
(5). The sequence was deposited in GenBank under acces-
sion no. KM881710, BioProject PRJNA263037.
For 14 of the 17 samples, high-throughput sequencing 
data were interpretable (online Technical Appendix Table); 
for the other 3 samples, the number of virus sequence reads 
was too low to distinguish them from sample cross-talk, 
which occurs during high-throughput sequencing analysis 
(6). Of the 14 typed samples, EV-D68 sequences were de-
tected in 7 of 10 samples from patients with severe disease, 
2 of 2 with moderate disease, and 0 of 2 with mild disease. 
The complete coding sequence was assembled from sample 
EV-D68_STL_2014_12. The most closely related genomes 
from previous seasons were Thailand, CU134, and CU171 
(7) (Figure, panel A). Several of the genome sequences ob-
tained from Missouri strains from this season, which had 
been sequenced by CDC, were very similar to this genome 
sequence. Comparison of the virus protein 1 sequence with 
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that of publicly available sequences indicated that the strain 
from St. Louis and the strain from Missouri (CDC) cluster 
with virus strains identified in Europe and Asia within the 
past several years (Figure 1, panel B). The St. Louis virus 
shared 97%–99% aa sequence identity with all other se-
quenced strains. We observed little variation in the strains 
from St. Louis because they shared 98%–99% nt sequence 
identity (online Technical Appendix Figure).
We provide a genome sequence from the 2014 out-
break of EV-D68 infection in St. Louis, Missouri. This 
sequence seems to be highly representative of the strains 
circulating in St. Louis during this time because the other 
genomes we partially sequenced are very similar. To our 
knowledge, no amino acids have been associated with vir-
ulence or increased infectivity of EV-D68; therefore, we 
cannot associate the changes we observed in these genomes 
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Figure. Phylogenetic comparison of 
enterovirus D68 (EV-D68) obtained from 
St. Louis, Missouri, USA, in 2014, with 
other sequenced strains. The phylogenetic 
relationships of genome sequences 
(nucleotides) were estimated by using the 
maximum-likelihood method with RAxML 
(http://www.viprbrc.org) bootstrapped 100 
times. A) Comparison of genome sequences 
for full-length and nearly full-length 
strains. B) Comparison of virus protein 1 
sequences. Sequences were downloaded 
from ViPR (http://www.viprbrc.org) and 
supplemented with strains from the 2014 
EV-D68 season. Sequences were clustered 
at 99% identity to obtain a representative set 
of sequences, which are shown. Bootstrap 
values are indicated on each tree. The strain 
from St. Louis is indicated by an asterisk on 
each tree. Scale bars indicate nucleotide 
substitutions per site.
to phenotypic traits. Because changes in the 5′ untranslated 
region have the potential to affect the rate of replication 
(8–10), it is possible that minor genome changes are re-
sponsible for the rapid spread and high severity of disease 
in 2014. Correlation between clinical features of patients in 
conjunction with additional genomic analysis might pro-
vide further insight into the pathogenetic determinants of 
this strain. Therefore the genome sequence of EV-D68 de-
termined from the 2014 outbreak in St. Louis, Missouri, 
provides a resource for tracking and genomic comparison 
of this rapidly spreading virus.
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To the Editor: Globally, epidemics of infection with 
hepatitis C virus (HCV) tend to be concentrated in correc-
tional facilities, according to a review of worldwide litera-
ture during 1990–2012 (1,2). Nearly 1 in 3 persons infected 
with HCV in the United States spends at least part of each 
year in either a prison or jail (3). Proficiency by correc-
tional health facilities in hepatitis C treatment by using the 
most effective agents may mitigate the predicted burden 
of end-stage liver disease and hepatocellular cancer in the 
coming years. The first wave of direct-acting agents against 
HCV had substantial side effects. Nonetheless, the New 
York Department of Corrections and Community Supervi-
sion (NYDOCCS) systematically approached the challenge 
of using these agents, and their experience serves as a les-
son that prison medical services can overcome substantial 
barriers to care.
In 2011, NYDOCCS piloted a hepatitis C treatment 
program for HCV genotypes 1a and 1b, comprised of tel-
aprevir, pegylated interferon, and ribavirin. Patients un-
derwent extensive mandatory pretreatment screening for 
mental health issues, pregnancy, and cirrhosis by using 
the FibroSURE assay (LabCorp, Burlington, NC, USA) 
and Doppler sonogram of the portal vein. Eligibility re-
quirements were a negative HIV test result, and liver fi-
brosis assessed either by liver biopsy or noninvasively, 
at METAVIR stage 2 or 3, or 4 (reference range 0–4) (4) 
with compensation. A patient in stage 1 was eligible if the 
patient had poor prognostic factors. An infectious disease 
consultant saw every patient; each patient received man-
datory patient education. Mandatory conditions for pa-
tients participating in the program were to sign a consent 
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